Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic identification of genomic nonresponse biomarkers to cancer therapies.

ESMO real world data and digital oncology·2026
Same author

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

ESMO open·2026
Same author

Prospective evaluation of genomics-guided off-label treatment.

Nature·2026
Same author

Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399].

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.

ESMO open·2025
Same author

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.

Lung cancer (Amsterdam, Netherlands)·2025

Related Experiment Video

Updated: Feb 20, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.5K

Molecular Tumor Boards: current practice and future needs.

D L van der Velden1, C M L van Herpen2, H W M van Laarhoven3

  • 1Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 19, 2017
PubMed
Summary
This summary is machine-generated.

Multidisciplinary Molecular Tumor Boards (MTBs) are crucial for integrating extensive tumor sequencing into cancer care. Establishing clear guidelines and harmonization is essential for optimizing MTB function and improving genomics-guided treatment.

Keywords:
Molecular Tumor Boardgenetics-guided cancer caretargeted therapywhole-genome sequencing (WGS)

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K

Related Experiment Videos

Last Updated: Feb 20, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.5K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K

Area of Science:

  • Oncology
  • Genomics
  • Clinical Genetics

Background:

  • Advances in tumor sequencing (whole-exome, whole-genome) are rapidly outpacing clinical knowledge and training.
  • This creates a gap in applying complex genetic information for targeted cancer therapies in standard care.
  • Multidisciplinary Molecular Tumor Boards (MTBs) are proposed solutions, but literature on their implementation and guidelines is scarce.

Purpose of the Study:

  • To evaluate current knowledge and unmet needs regarding MTBs.
  • To propose a strategy for successful MTB implementation in clinical practice.
  • To address the disparity between genetic potential and clinical application in cancer care.

Main Methods:

  • Literature review on MTBs and their role in cancer care.
  • Survey distributed to hospitals in The Netherlands regarding MTB access and function.
  • Analysis of experiences from a nationally operating MTB to inform implementation strategies.

Main Results:

  • Access to MTBs can enhance genetics-guided cancer care, but fewer than 50% of hospitals, and only 5% of non-academic ones, have access.
  • Existing MTBs exhibit significant variation in structure, tasks, and workflow, potentially impacting care quality and data sharing.
  • This heterogeneity hinders the development of a collaborative learning community for molecular tumor boards.

Conclusions:

  • MTBs are vital for governing extensive tumor sequencing in daily practice.
  • Successful MTB implementation requires global harmonization of sequencing practices, minimal operational/member requirements, and a clear unsolicited findings policy.
  • These prerequisites will optimize MTB performance and improve the interpretation and application of genomics-guided cancer care.